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Abstract
Background: Metformin decreases polycystic ovary syndrome (PCOS) symptoms, induces ovulation, and may improve
developmental competence of in vitro oocyte maturation. This study was designed to define the effects of metformin
on the characteristics of in vitro oocyte maturation in estradiol valerate (EV) PCOS-induced rats.
Methods: Forty-five adult female Sprague–Dawley rats were randomly divided into control; sham and PCOS-induced
(treated by a single dose of estradiol valerate, 4 mg/rat, IM) groups. The body weight was measured weekly
for 12 weeks. At the end of week 12, the serum levels of testosterone, estrogen, progesterone, LH, and FSH
and blood glucose of all the rats were measured. About 380 cumulus oocyte complexes (control, 125; sham,
122; PCOS-induced rats, 133) were incubated in Ham’s F10 in the absence and/or presence of metformin (M 5−10) for
12, 24, 36, and 48 h. The cumulus cells expansion and nuclear and cytoplasmic maturation of the oocytes was
evaluated using 1 % aceto-orcein staining, and transmission electron microscopy (TEM).
Results: No significant differences were observed in the body weight of the rats. The serum level of testosterone was
reduced, and progesterone and LH were significantly increased in the PCOS-induced rats (p < 0.05). However,
no significant differences were observed in the serum levels of estrogen and FSH among the groups. Blood
glucose level was higher in the PCOS-induced rats than control, (p < 0.01). The expansion of cumulus cells
was observed in the metformin-treated oocytes. The oocytes retrieved from PCOS-induced rats show a stage
of meiotic division (GVBD, MI, A-T, and MII) in 57.12 % of metformin-untreated and fairly significantly increased to
64.28 % in metformin-treated oocytes, (p < 0.05), but no differences were observed in the MII stage within groups. The
redistribution of some cytoplasmic organelles throughout the ooplasm, particularly the peripheral cortical granules, was
defined in the metformin-treated oocytes.
Conclusions: Single dose of EV can creates a reversible PCO adult rat model. Metformin enhances the COCs to initiate
meiotic resumption at the first 6 h of IVM. In our study the metformin inability to show all aspects of in vitro oocyte
maturation and may be resulted from deficiency of EV to induce PCOS.
Keywords: Polycystic ovary syndrome, In vitro oocyte maturation, Metformin
* Correspondence: mesbahf@sums.ac.ir
1Department of Anatomical Sciences, Shiraz University of Medical Sciences,
Shiraz 71348-53185, Iran
2Embryonic Stem Cell Lab, Shiraz University of Medical Sciences, Shiraz, Iran
Full list of author information is available at the end of the article
© 2015 Mesbah et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Mesbah et al. Journal of Ovarian Research  (2015) 8:74 
DOI 10.1186/s13048-015-0203-x
Background
Polycystic ovary syndrome is one of the major causes of
anovulatory infertility in women. The etiology and path-
ology of PCOS are still questioned, but imbalances of
testosterone, estrogen, progesterone, LH and FSH, obesity,
insulin resistance, and hyperinsulinemia are crucial factors
for ovarian hyperandrogenism and chronic anovulation
[1]. In addition to infertility, patients with PCOS are at a
risk of miscarriage [2], which has been reported during
the first trimester of pregnancy in approximately 30 to
35 % of patients [3].
The protocols proposed for the treatment of PCOS in-
clude a diet plan, exercise and physical activity, drug treat-
ments, and surgical procedures [4]. Drug treatments
include the administration of metformin, glitazones, spir-
onolactone, estrogen, and clomiphene citrate [5]. In recent
years, metformin alone or in combination with other
drugs is used to treat PCOS. Metformin, a biguanide anti-
hyperglycemic drug, is utilized to treat type 2 diabetes. In
women with PCOS associated with anovulation and resist-
ance to clomiphene citrate, the administration of clomi-
phene citrate in combination with metformin satisfactorily
increases the ovulation and pregnancy rate [6].
Many studies have reported that metformin can in-
duce oocyte maturation and improve oocyte quality [7].
However, the role of metformin in promoting in vitro
oocyte maturation remains unknown. The controversial
effects of metformin on in vitro maturation (IVM) of oo-
cytes have been demonstrated. Lee et al. demonstrated
the effects of metformin on the in vitro developmental
potential of porcine oocytes and embryos; further, they
clearly asserted that metformin augments the actions of
insulin as an insulin-sensitizing agent on the cytoplasmic
aspect of oocyte maturation and the preimplantation
embryonic development during in vitro production [8].
In addition, the administration of metformin in combin-
ation with oral contraceptives to women with PCOS can
increase the probability of in vitro oocyte maturation in
relation with miscarriage rate [9]. In contrast, Tosca et
al. demonstrated that metformin activates adenosine
monophosphate-activated protein kinase (AMPK), which
inhibits the germinal vesicle breakdown (GVBD) in cumu-
lus oocyte complexes (COCs) and most COCs arrested at
the germinal vesicle (GV) stage, but not denuded bovine
oocytes, [10]. Bilodeau-Goeseels et al. also reported that
metformin, as an activator of AMPK, inhibited GVBD in
bovine cumulus-enclosed oocytes and denuded oocytes
and that AMPK might play contradictory roles in the
regulation of bovine and murine oocyte maturation, [11].
Despite the ethical and technical restrictions on hu-
man experimentations, so far, the animal models that
can display all features of human PCOS has not been
well introduced. On the other hand, the effects of sup-
plements on the in vitro oocyte maturation to be clearly
determined, when all the main characteristics of PCOS
are observed. Sabatini et al. revealed that metformin re-
duced the IVM of oocytes of the wild type and leptin de-
ficient transgenic (ob/ob) mice models, but not in leptin
receptor mutant mice (db/db) models, [12]. The in vitro
maturation of oocytes consists of two principle features:
nuclear and cytoplasmic maturation [8]. Thus far, the
precise role of metformin in promoting all the aspects of
oocyte maturation in animal models of PCOS has not
been identified. The purpose of this study was that, des-
pite the fact that EV PCOS-induced rat model lack some
endocrine and metabolic features, whether metformin
contributes to the quality of the in vitro maturation of
oocytes? Therefore, the present study was designed to
investigate the effects of metformin as an additive sup-
plement on nuclear and cytoplasmic maturation as well
as the expansion of cumulus cells as the third criterion
of oocyte maturation in in EV PCOS-induced rats.
Methods
Experimental design
Forty-five adult female Sprague–Dawley rats (170–230 g)
were randomly selected from the animal house of Shiraz
University of Medical Sciences (SUMS). The animals were
reared under standard conditions (12 h of darkness; 12 h
of light; at 23 ± 2 °C), with ad libitum access to food and
tap water. The SUMS Ethics Committee approved all the
animal procedures. The animals were randomly classified
into three groups: PCOS-induced, which received a single
dose of EV, 4 mg/0.4 mL of olive oil/rat, IM, to induce
PCOS; sham, received only olive oil, 0.4 mL/rat, IM;
control, received no drug. This study was designed for a
period of 12 weeks, and all the animal groups were kept
under standard conditions in separate cages.
Measurement of weight, sex hormones and blood
glucose
For defining the characteristics of the animal model of
PCOS, the body weight of all the rats was measured once
a week for 12 weeks on the same day at the same time;
the serum levels of testosterone, estrogen, progesterone,
LH, and FSH and blood glucose were also assessed (radio-
immunoassay), at the end of week 12.
Histological study
To recognize the presence of cystic follicles in PCOS-
induced rats, paraffinzed blocks of the ovaries were pre-
pared. The blocks were cut into 5-μm-thick sections,
stained with hematoxylin-eosin, and observed by a light
microscope.
Oocyte collection and in vitro maturation
After 12 weeks, the rats were sacrificed and the ovaries ex-
cised to acquire COCs. The COCs with a homogeneous
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ooplasm and at least two layers of cumulus cells were se-
lected for IVM. The COCs of each group were divided
into two subgroups and incubated in Ham’s F10 (Cat. No.
T 071–01) supplemented with 2.1 mg of sodium bicar-
bonate/mL, 75 μg of penicillin G/mL, 75 μg of strepto-
mycin/mL and 5 % human serum albumin, in the absence
and/or presence of metformin (M 5−10) for 12, 24, 36, and
48 h. The concentration of metformin (M 5−10) was
assigned based on the results of Lee et al. but not different
concentration, because they have demonstrated that dif-
ferent concentrations of metformin alone does not affect
the in vitro maturation of oocyte [8]. One of the sub-
groups of oocytes was stained with an aceto-orcein (1 %)
solution to define nuclear maturation as the assortment of
GV, GVBD, metaphase I (MI), anaphase-telophase (A-T),
and MII, and as degenerated and non-detectable by using
a light microscope [13, 14]. Cultured denuded oocytes
were placed in the center of glass slide, covered and com-
pressed gently with a cover slid which attached to the glass
slid by a paraffin-vaseline wax bar on each corner of cover
slid to hold and fixed them in acid acetic and methanol
(1:3, v/v) for 24 h. Oocytes were stained with 1 % fresh
aceto-orcein (1 % orcein in 45 % glacial acetic acid) by
pushing aceto-orcein solution between glass slid and cover
slid using insulin syringe, and immediately observed by
light microscope. To prepare a 1 % aceto-orcein solution,
55 mL of glacial acetic acid was boiled and poured over
1 g of orcein powder. The solution was cooled, and 45 mL
of distilled water was added to it.
Evaluation of the expansion of cumulus cells
In both subgroups of oocytes, the expansion of cumulus
cells was evaluated using a modification of the method
described by Nandi et al. [15] and was categorized as fol-
lows: complete expansion (almost all cumulus cells dis-
persed around the oocytes in a colloidal matrix), semi
expansion (the cumulus investment had been initiated
for the expansion and was partially dissociated), no expan-
sion (none of the cumulus cells were expanded and they
were adherent to the zona pellucida), and degeneration.
Oocyte preparation for transmission electron microscopy
The other subgroup of oocytes was fixed overnight in
Karnovsky’s solution (2.5 % glutaraldehyde and 2 % para-
formaldehyde in 0.1-M sodium cacodylate buffer) and
post-fixed in 1 % OsO4 in 0.1-M sodium cacodylate buf-
fer for 90 min. The samples were then dehydrated by
passing them through an ethanol series, embedded in
Epon 812 (TAAB, Aldermaston Berkshire, UK), and fi-
nally sectioned into semi-thin (1-μm-thick) slices. The
sections were mounted on glass slides and stained with
toluidine blue; they were examined using a light micro-
scope. The tissue blocks were retrimmed and ultrathin
(60–90 nm) sections were taken. These sections were
collected on copper grids, stained with uranyl acetate for
15 min and lead citrate for 12 min at room temperature,
and examined using TEM (Philips CM10, Amsterdam,
Netherlands).
Statistical analysis
To analyze the data related to the weight and the serum
hormone levels, SPSS ver. 15 (SPSS Inc., Chicago, IL,
USA) was used, and the weights of the rats were com-
pared by mixed model analysis, and the serum level of
hormones with one-way analysis of variance and post-
hoc least significant difference. A chi-squared test was
used to compare the rate of cumulus cell expansion and
that of in vitro COCs maturation within the groups.
Results
Measurement of weight, sex hormones and blood
glucose
The gain in body weight of the rats within the groups
showed a growing trend, the mean (±SD) of the body
weight of the rats from week 1 to week 12 increased from
186.20 ± 6.40 to 205.06 ± 3.50 g in the control group, from
186.60 ± 4.53 to 205.60 ± 2.10 g in the sham group, and
from 170.26 ± 5.67 to 192.13 ± 2.10 g in the PCOS-
induced group, although no significant differences were
observed in the body weight of the rats.
The serum level of testosterone decreased, while the
progesterone and LH significantly increased in the experi-
mental rats (p < 0.05). No significant differences were ob-
served in the estrogen and FSH levels in the three groups
(Table 1). Blood glucose level was significantly increased
the PCOS-induced (184.40 ± 11.03 mg/dL) vs control
(154.40 ± 13.52 mg/dL) rats, (p < 0.01).
Histological observations
The histological features of the ovaries under the light
microscope showed cystic and relatively degenerated
follicles in the PCOS-induced rats (data not shown
here and published previously as mention and cited
in discussion section).
Table 1 Serum levels of testosterone, estrogen, progesterone,
FSH, and LH in rats
a Control Sham PCOS
(15 rats) (15 rats) (15 rats)
Testosterone (ng/mL) 0.180 ± 0.068 0.180 ± 0.057 0.130 ± 0.031a)
Estrogen (pg/mL) 11.120 ± 1.460 10.970 ± 0.470 11.570 ± 0.870
Progesterone (pg/mL) 50.990 ± 9.974 50.770 ± 6.678 56.700 ± 4.400a)
FSH (ng/mL) 3.140 ± 0.350 3.790 ± 0.310 3.230 ± 0.470
LH (ng/mL) 0.160 ± 0.010 0.200 ± 0.030 0.760 ± 0.050a)
PCOS polycystic ovary syndrome
a)Significant differences from the control and sham groups (p < 0.05)
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In vitro oocyte maturation
Out of the 380 COCs cultured in all groups for 12, 24, 36,
and 48 h, the cumulus cells of 53.03 % and 32.83 % of the
COCs in the PCOS-induced rats in the metformin-treated
and-untreated groups had expanded completely (Fig. 1a),
30.30 % and 25.374 % had semi-expanded, 15.15 % and
34.32 % had not expanded (Fig. 1b), and 1.51 % and 7.46 %
had degenerated, respectively (Table 2). The cumulus cells
in 64.21 % of the COCs had completely expanded and/or
semi-expanded in the absence of metformin, and had in-
creased to 88.94 % in the presence of metformin in all the
rats. In addition, in the PCOS-induced rats, the percentage
of completely expanded and semi-expanded cumulus cells
increased from 58.20 to 83.33 %. The total proportion of
COCs with no expansion of the cumulus cells decreased
from 30.00 % in the absence of metformin to 10.00 % in
the presence of metformin. These results demonstrate that
the rate of complete expansion and semi-expansion of the
cumulus cells increased significantly, and the percantage
of unexpanded cumulus cells decreased significantly in the
presence of metformin (p < 0.05).
The nuclear maturation of oocytes was evaluated in
the three groups: of 172 oocytes, 21 oocytes were in GV,
34 in GVBD (Fig. 2a), 37 in MI (Fig. 2b), 10 in A-T, 28
in MII, and 13 in degeneration; 29 were indistinguish-
able (Table 3). As mention in table 3, totally, 61.62 % of
COCs show one of the stages of meiotic division (sum of
GVBD, MI, A-T, and MII) in the absence of metformin
(in total column of “without metformin”) and signifi-
cantly increased to 65.11 % in the presence of metformin
(in total column of “with metformin”), while in PCOS-
induced rats, a fairly significant increase from 57.12 % in
metformin-untreated oocytes to 64.28 % in metformin-
treated oocytes, (p < 0.05). No significant differences in
the MII stage within the metformin-treated and -un-
treated COC groups were seen.
Light and electron microscope observations
The observation of semi-thin and ultrathin sections of
COCs by a light (Fig. 3a, b, c) and a TEM (Fig. 4a, b, c,
d, e, f ) at different times in normal and PCOS-induced
rats incubated with and without metformin, revealed the
following features: a decrease in the number of connec-
tions between cumulus cells and each cell dispersed
from the other; presence of many small and dark granu-
losa cells; decreased cytoplasmic projections of cumulus
cells and oocytes in the zona pellucida; enlargement of
the perivitelline space (PVS), particularly during 12–36 h
of incubation; and redistribution of some cytoplasmic
organelles, particularly cortical granules which close to
the oolemma. However, polar bodies and Golgi com-
plexes were not observed. Degenerated cells were ob-
served in cumulus cell in metformin-treated group and
non-uniform ZP, non-obvious oolemma and narrow PVS
were noticed in the absence of metformin.
Discussion
Because of ethical and technical restrictions on human ex-
perimentation, researchers have used animal PCOS
models. The animal models of PCOS have proven useful
in determining the causes of PCOS, to perform preclinical
trials, and to examine ovarian morphology, hormonal dis-
orders, and the pathogenesis of anovulation in PCOS.
Thus far, a persuasive animal model that can replicate all
features of human PCOS has not been established. Among
mammals, despite the fact that rhesus monkeys and sheep
show major ovarian morphological changes [16], rodents
are versatile and a more suitable and unique animal for
PCOS models [17, 18]. Compare to rhesus monkeys and
sheep, rats and mice are inexpensive, readily available, and
Fig. 1 Cumulus oocyte complex expansion, (a) expanded COCs,
cultured for 48 h in the presence of metformin in PCOS- induced
(400×); (b) Non-expanded COCs, cultured for 24 h in the absence of
metformin from the control rats (200×). ZP, zona pellucida; Oo, oocyte
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easy to handle and maintain [16], they have a short repro-
ductive cycle, short estrous cycles, and a short gestational
period [17, 19]. Rodent models of PCOS have shown
hyperandrogenism and hormonal alteration; ovarian mor-
phological changes, including the presence of multi-cystic
follicles; and metabolic disorders [17]. Rodent models of
PCOS can be attained by a variety of methods, including
constant exposure to light [20], genetic manipulation [17],
and administration of hormones, such as testosterone (T)
[17], dihydrotestosterone (DHT) [21], EV [22, 23], and
letrozole (a non-steroidal aromatase inhibitor) [21, 24].
Among these hormones, T, DHT, and letrozole show
many characteristics of human PCOS, including acyclicity,
anovulation, polycystic ovaries, hyperandrogenism, and in-
sulin resistance [17]. These features are dependent on the
dose of hormones, menstrual cycle phase and duration of
treatment, and the waiting time for induction of PCOS
[25]. Several injections and/or gavages of T, DHT, and
letrozole are likely to increase the possibility of stress and
high mortality rates during the experiment and it is also a
time-consuming method. However, after a single injection
of the EV, it will take about 8–12 weeks to induce PCOS,
therefor the stress of injection is reduced, it is well known
that stress causes irregularities in the menstrual cycle. The
EV-induced PCOS model displays characteristic morpho-
logical alterations in the ovary [26], particularly the multi-
cystic follicle; as previously shown [27, 28], and mention
shortly in results section, which is typically observed in
human PCOS. In addition, the EV-induced PCOS model
is used in many laboratories, develops hypertension and
increases sympathetic activity [29]; these effects lead to in-
creased blood glucose as in this study and it is utilized for
autoimmune disorder responses in PCOS [30]. However,
the major restrictions of the EV-induced PCOS model are
a lack of exactly endocrine and metabolic features associ-
ated with human PCOS [17]. It seems that EV can creates
a reversible PCO adult rat model, but not PCOS [16, 31,
32], Gonzalo Cruz et al. established an irreversible PCO
model when neonatal rat exposure to EV [33]. Recently,
Caldwell et al. have demonstrated that long-term DHT
Table 2 Expansion of cumulus cells of rat cumulus oocyte complexes in control, sham, and PCOS groups in the absence or
presence of metformin
Groups Without metformin With metformin
Control Sham PCOS Total Control Sham PCOS Total Total
N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%)
Expansion 25 (40.32) 25 (40.98) 22 (32.83) 72 (37.98) 34 (53.96) 35 (57.37) 35 (53.03)a) 104 (54.73)a) 176 (46.31)
Semi expansion 16 (25.80) 17(27.86) 17 (25.37) 50 (26.31) 22 (34.92) 23 (37.70) 20 (30.30) 65 (34.21)a) 115 (30.26)
No expansion 19 (30.65) 15 (24.59) 23 (34.32) 57 (30.00) 7 (11.11) 2 (3.27) 10 (15.15)a) 19 (10.00)a) 76 (20.00)
Degeneration 2 (3.23) 4 (6.55) 5 (7.46) 11 (5.78) 0 (00.00) 1 (1.63) 1 (1.51)a) 2 (1.05)a) 13 (3.43)
Total 62 61 67 190 63 61 66 190 380
PCOS polycystic ovary syndrome
a)Significant differences from the absence of metformin (p < 0.05)
Fig. 2 Light micrographs of nuclear maturation of oocytes cultured
for, (a) 48 h in the presence of metformin at germinal vesicle breakdown
(arrow) from the control; (b) 12 h in the presence of metformin
at meiosis I (arrow) from the PCOS-induced rats. Aceto-orcein
staining (1000×)
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administration in mice imitates an extensive of PCOS fea-
tures [34].
The results of this present study show that a single
intramuscular injection of EV induces experimental PCOS
in rats, which can be identified by observing the cystic and
atretic follicles as previously indicated in our laboratory
[27, 28] and alterations in the serum levels of gonadotro-
pins and increases blood glucose level. In our study, as in
the study of Stener-Victorin et al. [29], EV may affect the
hypothalamic–pituitary–adrenal axis and the ovary, fol-
lowing a hormonal disorder. Various PCOS animal models
have shown dissimilar hormonal changes, but our findings
confirm the results of studies by Singh [19], and Stener-
Victorin et al. [29], who have reported alterations in the
serum levels of gonadotropins.
Obesity is a subordinate symptom of PCOS in women
[1]. In this study, weight gain in the PCOS-induced rats
was lower than that in the control rats, which is compar-
able with the results of Stener-Victorin et al. [29]. The
administration of EV increases adrenal glucocorticoid
production, which enhances lipid metabolism, and leads
to a decrease in the body weight [29]. However, the obes-
ity is not always observed in women with PCOS [35, 36].
In addition, the amplification of sympathetic activities in
women with PCOS was found to increase lipid metabol-
ism and body activity, and consequently, decreases the
body weight [31].
Metformin is an insulin-sensitizing drug [8, 37], usually
prescribed in patients with PCOS, to induce ovulation, re-
duce the symptoms of hyperinsulinemia [8], and improve
insulin sensitivity to decrease the serum levels of androgen
[37]. It has been reported that metformin contributes to
in vitro maturation of oocytes, which are collected from
patients with PCOS [38], and associated with insulin, but
not alone, have beneficial effects on oocyte maturation,
oocyte quality and production of embryo [8]. Metformin
improves the action of insulin on oocyte glutathione
(GSH) content, which knocks out the free radicals in
the oocytes, resulting in enhanced oocyte competence
[37]. These results suggest that metformin accompany
with insulin may increase the cytoplasmic maturity of
oocytes during IVM. Mansfield et al. demonstrated that
metformin in the culture medium has a direct effect on
cumulus and theca cells and mediates enzyme activities
for the synthesis of steroid hormones. In addition, met-
formin has inhibitory effects on progesterone and estra-
diol production on the in vitro culture of granulosa
cells; progesterone is the secreted end point in the ster-
oid synthesis pathway in these cells [39]. Progesterone
plays a role in bovine oocyte maturation, particularly in
cytoplasmic maturation, but represents a different role
and is dependent on cells (oocyte and/or cumulus cells)
and the cell progesterone receptors [40]. In addition,
progesterone induces meiosis resumption in cultured bo-
vine COCs in a concentration-dependent manner [41].
Our data show that metformin does not affect all fea-
tures of nuclear and/or cytoplasmic maturation. These
controversial effects of metformin on nuclear and
cytoplasmic maturation lead us to believe that the EV-
induced PCOS animal model does not clearly present
all the features of hyperandrogenism and hypergly-
cemia. It has been reported that metformin is more
effective in a batch of transgenic PCOS-induced mice
that categorized by hyperleptinemia and hyperinsuli-
nemia [12]. The lacks of our study are that we have
not measured leptin and insulin levels, but hypergly-
cemia was observed in the EV-induced PCOS animal
model, which it may be due to the increase in sympa-
thetic activity [29]. In the other hand it is believed that
patients with the most obvious hyperandrogenism
have most benefited from metformin treatment [42],
therefore, in our study the metformin inability to show
all aspects of in vitro oocyte maturation and may be
resulted from deficiency of EV to induce PCOS.
Table 3 Nuclear maturation of rat oocytes in control, sham, and PCOS groups in the absence and presence of metformin
Groups Without metformin With metformin
Control Sham PCOS Total Control Sham PCOS Total Total
N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%)
GV 4 (13.79) 3 (10.34) 4 (14.28) 11 (12.79) 3 (10.34) 4 (13.79) 3 (10.71) 10 (11.62) 21 (12.20)
GVBD 6 (20.68) 5 (17.24) 5 (17.85) 16 (18.60) 6 (20.68) 6 (20.68) 6 (21.42)a 18 (20.93) 34 (19.76)
MI 6 (20.68) 6 (20.68) 5 (17.85) 17 (19.76) 7 (24.13) 7 (24.13) 6 (21.42) a 20 (23.25) 37 (21.51)
A-T 1 (3.44) 3 (10.34) 2 (7.14) 6 (6.97) 1 (3.44) 1 (3.44) 2 (7.14) 4 (4.65) 10 (5.81)
MII 5 (17.24) 5 (17.24) 4 (14.28) 14 (16.27) 5 (17.24) 5 (17.24) 4 (14.28) 14 (16.27) 28 (16.27)
Deg 2 (6.89) 2 (6.89) 3 (10.71) 7 (8.13) 2 (6.89) 1 (3.44) 3 (10.71) 6 (6.97) 13 (7.55)
ND 5 (17.24) 5 (17.24) 5 (17.85 15 (17.44) 5 (17.24) 5 (17.24) 4 (14.28) 14 (16.27) 29 (16.86)
Total 29 29 28 86 29 29 28 86 172
PCOS polycystic ovary syndrome; GV germinal vesicle; GVBD germinal vesicle breakdown; MI metaphase I; A-T anaphase-telophase; MII metaphase II; Deg.
degenerated; ND not-detectable
a)Significant differences from without metformin, (p < 0.05)
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It is clearly known that the expansion of cumulus cells
of COCs is a criterion for oocyte maturation. Nagyova
reviewed the mechanisms involved in ovarian follicular
processes, including the expansion of cumulus cells, the
hyaluronan synthesis and progesterone production in
COCs. The expansion of cumulus cells in mouse, por-
cine, bovine, and rat depends on a specific factor, “cu-
mulus expansion enabling factor”, which secreted by the
oocytes and/or in some mammals, by cumulus cells [43].
It was concluded that optimal cumuli expansion pro-
motes embryonic development in bovine oocytes. It is
suggested that glutathione is needed for the expansion
of cumulus cells and that hyaluronan accumulates in the
expanded cumulus cells. Hyaluronan, which builds up
within cumulus cells in porcine COCs during cumuli
expansion, disrupts cell junctions of COCs and pro-
motes meiotic resumption in oocytes [44]. Our findings
concur with those of previous studies and show that in
the presence of metformin in PCOS-induced rats, a
higher number of cumulus cells of COCs (53.03 %) are
completely expanded as compared to those in the ab-
sence of metformin (32.83 %). However, this contradicts
the findings of Tosca et al. who concluded that metformin
inhibits cumuli expansion and oocyte meiotic resumption
in bovine COCs (not denuded oocytes), [45]. These results
indicate that the presence of metformin in the culture
medium may enhance the expansion of cumulus cells, but
not in PCOS-induced rats, because metformin acts first
on cumulus cell to dissociate around the oocyte [45]. Des-
pite of metformin has a role on the resumption of meiotic
division, a small percentage of oocytes reaches to MII
stage. Bilodeau-Goeseels et al. reported that both metfor-
min and aminoimidazole- carboxamide ribofuranoside
(AICAR) (activators of AMPK) have inhibitory effects on
cumulus cells expansion and nuclear maturation in bo-
vine, but not mouse and are greater in COCs than in
denuded oocytes due to the presence of cumulus-oocyte
projections [11]. Also Nicolas reported that AMPK has
same effects on cumulus cells expansion and nuclear
maturation in porcine [46]. Metformin decreased proges-
terone and estradiol productions in vitro in human, rat
and bovine granulosa cells [10, 39]. In relevant to the spe-
cies, different mechanisms involved on estradiol produc-
tion in granulosa cells and metformin may also reduce
steroid levels in granulosa cells from follicular cysts. [10].
Increased estradiol and progesterone concentrations have
been reported in the ovarian cyst [47].
Fig. 3 Light micrographs of oocytes cultured for, (a) 12 h in the
absence of metformin in the normal; (b) 24 h in the absence of
metformin in the PCOS-induced; (c) 36 h in the presence of metformin
in the PCOS-induced rats. Few atretic and dark small cumulus cells
noticed in (c). Resinate 1 μm-sections, toluidine blue staining (400×).
ZP, zona pellucida; Oo, oocyte; CC, cumulus cells
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Resumption of meiotic division is the other principle
of oocyte maturation and takes place largely in IVM. In
our study, resumption of meiotic division was slightly in-
creased in the presence of metformin, particularly in the
PCOS-induced rats. Although the resumption of oocyte
meiotic division is the first step of oocyte maturation,
completion of oocyte maturation occurs when the oo-
cyte reaches to the MII stage. In contrast to bovine [45]
and porcine [48], which metformin arrested COCs at the
GV stage, in our study 65.11 % of COCs were initiated
meiotic resumption at the first 6 h of IVM in metformin
supplemented medium. While, in PCOS-induced rats a
fairly significant increase from 57.12 % in metformin-
untreated oocytes to 64.28 % in metformin-treated oo-
cytes. Our data show that, no differences were observed
in the percentage of the MII stage between metformin-
treated and –untreated oocytes, as reported in bovine
[45], these data clearly show that low percentage of oo-
cytes reached to the MII of maturation. Thus, the nu-
clear maturation of oocytes in the PCOS-induced rats
may be not affected by metformin. Tosca et al. reported
that metformin decreases the number of cumulus and
theca cells to generate steroid hormone genes, thus in-
directly promoting the nuclear maturation of oocytes
[10]. In contrast to our findings, Bilodeau-Goeseels et al.
concluded that metformin activates AMPK, which in-
hibits GVBD in bovine COCs and denuded oocytes, but
enhances oocyte meiotic resumption in mice, which is
similar to that observed in the PCOS-induced rats in
our study. Several studies also reported that AMPK may
have contradictory roles in the management of bovine
and murine oocyte maturation; it seems that a different
mechanism is used to stimulate AMPK in rodents [11].
The difference between the rate of cumulus cell expansion
Fig. 4 Electron micrographs of oocytes cultured for, (a) 12 h in the absence of metformin from the PCOS-induced (1500×); (b) 12 h in the presence
of metformin from the PCOS-induced, the arrows denote the cortical granules (8900×); (c) 24 h in the presence of metformin from the normal,
the arrows denote the cortical granules (3200×); (d) 24 h in the presence of metformin from the PCOS-induced, degenerated cumulus
cells were noticed. (1650×); (e) 36 h in the absence of metformin from the normal, degenerated cumulus cells were noticed. (3900×); (f) 36 h in the
presence of metformin from the normal rats, PVS filled by microvilli. (1150×). ZP, zona pellucida; CC, cumulus cells; Oo, oocyte; Mt, mitochondria; PVS,
perivitelline space; MV, microvilli
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and nuclear maturation in PCOS-induced rat in presence
and absence of metformin, may be as a result in a lack of
orchestration between these phenomena.
Cytoplasmic maturation is a criterion for deducing the
developmental competence of oocyte maturation in vitro
and includes numerous morphological and biochemical
features. The morphological changes include the reduc-
tion of the Golgi complex volume, increase in the number
of lipid droplets and cortical granules, and enlargement of
PVS [49]. The results of this study at the level of light and
electron microscopy show that metformin influences few
features of oocyte maturation. Cumulus cells around the
oocytes in the metformin-treated group were dark, due to
nuclear heterochromatin [50], and had lower cell density
than the other groups. However, Nottola et al. [51] dem-
onstrated that the presence of dark cumulus cells is re-
lated to the accumulation of lipid droplets in the ooplasm,
which shows active steroidogenesis in healthy and mature
granulosa cells. Our data show that the number of cell
junctions between the other cumulus cells and oocytes
were decreased, and these tended to expand. According to
the findings of Tosca et al. [10], metformin reduces the
production of steroids and enzymes in cumulus cells and
consequently, causes a decrease in the number of connec-
tions between cumulus cells and oocytes; thus, cumulus
cells initiate the expansion. Our findings on the effects of
metformin, such as a declining trend of cellular links and
redistribution of some cytoplasmic organelles, corroborate
the findings of Suzuki et al. [52] with human oocytes and
granulosa cells cultured in Ham’s F-10. An increase in the
number of apoptotic cells was observed in cumulus cell in
the metformin-treated group. Note that a non-uniform
zona pellucida, non-obvious oolemma, and narrow PVS
were observed in the absence of metformin. It is well
known that the enlargement of PVS is a morphological
change in matured oocytes [49, 53]. As we have shown,
the presence of cortical granules close to the inside of
oolemma is a symptom of oocyte maturation, which is re-
quired to prevent polyspermy [54].
Conclusions
This study demonstrated that single dose of EV can cre-
ates a reversible PCO adult rat model, but not PCOS, it
has no effect on the body weight of rats, but modifies
sex hormones and blood glucose level. The results of
this study revealed that, metformin enhances the COCs
to initiate meiotic resumption at the first 6 h of IVM,
but the most of the COCs have never completed meiotic
division and the percentage of the MII stage is the same
in metformin-treated and –untreated oocytes in EV
PCOS-induced rats. In our study the metformin inability
to show all aspects of in vitro oocyte maturation and
may be resulted from deficiency of EV to induce PCOS.
The results of this study suggest that further studies
including, assessment of glucose; insulin and leptin level;
pre-treatment in vivo and deferent concentration of met-
formin; and spindle assembly detection are needed to
evaluate the metabolic features and effects of metformin
on oocyte at the molecular and cellular levels through-
out the IVM of oocytes retrieved from EV PCOS-
induced rat.
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